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Chlorosulfonyl isocyanateAbstract A series of novel N-acylsulfonamide derivatives were synthesized and characterized by
1H NMR, 13C NMR and HRMS. The N-acylsulfonamides were prepared in four steps (carbamo-
ylation, sulfamoylation, deprotection and acylation) starting from chlorosulfonyl isocyanate. These
compounds were evaluated in vitro as antimicrobial agents against representative strains of Gram-
positive (Staphylococcus aureus) and Gram-negative (Escherichia coli, Acinetobacter, Klebsiella
pneumonia and Pseudomonas aeruginosa).
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The N-acylsulfonamide functional groups are found within
numerous marketed agents for a wide range of therapies. In re-
cent years, molecules containing acylsulfonamides have also
been investigated as HCV protease inhibitors, (Raboisson
et al., 2009) CXCR2 antagonists (Winters et al., 2009) and aryl
acylsulfamide structures have been disclosed in a number of
pharmaceutical patents as potential therapeutic agents with
wide ranging biological activities (Reitz et al., 2009). NewN-acylsulfonamides were recently described such as 1. These
compounds exhibit potent antiproliferative activity in three
human tumor cell lines (Hep G2, PC-3 and B16-F10) (Huan-
qiu et al., 2012). The macrocyclic indole-base 2 inhibitors of
the HCV NS5b polymerase (Vendeville et al., 2012) targeting
the ﬁnger loop domain led to the discovery of lead compounds
exhibiting improved potency in cellular assays and superior
pharmacokinetic proﬁle.
The most practical methods for the synthesis of N-acylsulf-
onamides, involve the reaction of parent sulfonamide with acyl
chlorides or anhydrides in basic conditions (Kondo et al.,
2000, 1998; Ishizuka et al., 2000; Huang et al., 2006). Acylation
of sulfonamides with concentrated H2SO4 in carboxylic acid
anhydride as solvent (Morisawa et al., 1980) or in acetonitrile
(Martin et al., 2003) is one of the less common reports men-
tioning this transformation under acidic conditions. Another
approach utilizes palladium-catalyzed carbonylation of aryl
and heteroaryl halides with sulfamides utilizing microwave
irradiation and vials pre-pressurized with carbon monoxide
gas (Roberts et al., 2010).
Scheme 1 Preparation of N-acylsulfonamides.
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Figure 1 Examples of N-acylsulfonamide-containing drugs.
Figure 2 Structure of novel N-acylsulfonamides.
S1096 M. Berredjem et al.Herein, we report the synthesis of novel N-acylsulfona-
mides S1, S2, S3 starting from chlorosulfonyl isocyanate by
four steps carbamoylation, sulfamoylation, deprotection and
acylation (Bouasla et al., 2011; Cheraiet et al., 2012). We have
investigated the antibacterial activities of N-acylsulfonamides
S1, S2 and S3 against Gram-positive Staphylococcus aureus
ATCC25923 (b6), S. aureus isolate (b1), Gram-negative Esch-
erichia coli ATCC25922 (b5), E. coli (clinical isolate) (b2),
Klebsiella pneumonia (clinical isolate) (b4), Pseudomonas aeru-
ginosa ATCC 27853 (b7) and Acinetobacter (sp.) (clinical iso-
late) (b3) by both disk diffusion and minimal inhibition
concentration (MIC) methods.Figure 3 Results of the MIC of the various bacterial strains for
the sulfonamides S1, S2 and S3.2. Chemistry
As part of the research for new derivatives of sulfonamides, we
found that chlorosulfonyl isocyanate is a suitable reagent
allowing the introduction of sulfonamide moiety in diverse
molecules (Berredjem et al., 2003; Barbey et al., 2012; Bendjed-
dou et al., 2006; Khettache et al., 2006).
N-acylsulfonamides (Scheme 1) are prepared in four steps
(carbamoylation, sulfamoylation, deprotection and acylation)
by the reaction of chlorosulfonyl isocyanate (1 equiv.) and ter-
tiobutanol (1 equiv.) in anhydrous CH2Cl2 (20 mL). After
30 min, the N-Chlorosulfonylcarbamate was added to a solu-tion of primary or secondary amines (1 equiv.) in the same sol-
vent (20 mL) in the presence of triethylamine (1.1 equiv.) at
0 C. The resulting mixture was stirred for less than 2 h at
room temperature. The reaction mixture was washed with
HCl 0.1 N and water, the organic layer was dried over anhy-
drous magnesium sulfate and concentrated in vacuum. The
residue was puriﬁed by chromatography on silica gel (eluted
with CH2Cl2) to give 85% of N-Boc sulfonamide as white
solid.
The protected sulfonamides 1a–1c reﬂuxing in water for less
than 15 min afforded deprotected sulfonamides 2a–2c with
quantitative yield. Preparation of N-acylsulfonamides 3a–3c
Figure 4 Diameters of zone inhibition of the bacterial strains with respective sulfonamides S1, S2, S3 and Cip.
Synthesis and antibacterial activity of novel N-acylsulfonamides S1097was carried out by the reaction with obtained sulfonamides
and acetic anhydride in acetonitrile in the presence of H2SO4
for 1 h.
3. In vitro antibacterial activity
During our study, the antibacterial activity of compounds was
screened against various pathogens in vitro by using disk diffu-
sion and micro dilution methods. Ciproﬂoxacin was used as
control. The results of the synthesized compounds are shown
in Figs. 1 and 2.
As seen in Figs. 1 and 2, S1 showed an antibacterial activity
against all Gram negative referenced bacteria (E. coli
ATCC25922 (b5), P. aeruginosa ATCC 27853(b7)) and clinical
isolate (E. coli (b2), K. pneumonia (b4) and Acinetobacter (sp.)
(b3)) at 500 lg/mL. The inhibitory diameters varied between
10 and 15 mm. All the clinical isolates used were resistant to
ciproﬂoxacin.
S2 and S3 have higher diameters going to 40 mm for P.
aeruginosa ATCC27853 (b7). Concentrations are 3.9 lg/mL
and 31.25 lg/mL. respectively Figs. 3 and 4.
No activity was exhibited on S. aureus.
From the results obtained it comes out that no activity on
the Gram positive bacteria was noted with our synthesized sul-
fonamides. On the contrary good activity was obtained on all
the Gram negative bacteria used with S1.
The highest activity on P. aeruginosa (b7) was obtained
with S2 at 3.9 lg/mL.
The solvent control did not show any antimicrobial
activity.
4. Conclusion
In conclusion, we have developed a new and efﬁcient route to
N-acylsulfonamides. All compounds demonstrated an activity
on clinical isolate and referenced Gram negative bacteria. Fur-ther research in this area is in progress. Consequently these
synthesized compounds may be suggested for industrial
applications.5. Experimental section
5.1. General
Melting points were determined in open capillary tubes on an
Electro thermal apparatus and uncorrected. IR spectra were
recorded on a Perkin–Elmer FT-600 spectrometer. Proton nu-
clear magnetic resonance was determined with a 360 WB or
AC 250 MHz Bruker spectrometer using CDCl3 and DMSO-
d6 as a solvent and TMS as an internal standard. Chemical
shifts are reported in d units (ppm). All coupling constants
(J) are reported in Hertz. Multiplicity is indicated as s (singlet),
d (doublet), t (triplet), m (multiplet) and combination of these
signals. Electron ionization mass spectra (30 eV) were recorded
in positive mode on a Water MicroMass ZQ. All reactions
were monitored by TLC on silica Merck h60 F254 (Art.
5554) percolated aluminum plates and were developed by
spraying with ninhydrin solution.
Clinical isolates from parietal distal takings of patients’ S.
aureus (b1), E. coli (b2), Acinetobacter sp (b3) and K. pneumo-
nia (b4) cultures were obtained from the laboratory of micro-
biology – CHU DORBAN.
We used, as control, three referenced strains: S. aureus
ATCC 25923 (b6), E. coli ATCC 25922 (b5) and P. aeruginosa
ATCC 27853(b7).
Minimal inhibitory concentrations (MIC) were determined
by the micro dilution broth method following the National
Committee for Clinical Laboratory Standard’s procedures
(Wayne, 1997a, 1997b). MIC are deﬁned as the lowest concen-
trations of the antimicrobial agents that inhibited visible
growth of the micro-organism. All tests were performed in
Mueller Hinton Broth (MHB). The compounds under the test
S1098 M. Berredjem et al.were dissolved in analytically pure dimethylsulfoxide (DMSO)
and geometric dilutions ranging from 0.97 to 500 lg/mL of the
compounds.
Inhibition zones of (S1), (S2) and (S3) were determined by
the disk dilution method (Brunton et al., 2006). The culture
suspensions were prepared and adjusted by comparing against
0.3 Mc Farland turbidity tubes. Mueller–Hinton Agar (20 mL)
was poured into each sterile Petri dish after injecting cultures
(100 lL) of microorganisms and distributing medium in Petri
dish homogeneously. Compounds were dissolved in DMSO
of 10 mg/mL to prepare stock solution. Empty sterilized disks
of 6 mm were impregnated with 50 lL of compounds at the re-
quired concentrations of 0.97–500 lg/mL. Disks were placed
on agar plates and the cultures were incubated at 37 C for
24 h. The evaluation of the inhibition zones formed on the
medium was in mm. Reference disk used for control is cipro-
ﬂoxacin (Cip, 5 lg).
To insure that the solvent had no effect on the bacterial
growth, a control was performed at the test medium supple-
mented with DMSO at the same dilutions as used in the
experiments.
5.2. General procedure for the synthesis of carboxylsulfonamide
A solution of tertiobutanol (2.27 g, 14.1 mmol) in anhydrous
CH2Cl2 (10 ml) was added to a stirring solution of chlorosul-
fonyl isocyanate (CSI) (1.23 ml, 14.1 mmol) in (10 ml) of anhy-
drous CH2Cl2 at 0 C dropwise over a period of 10 min. The
resulting solution was transferred to a mixture of primary or
secondary amine (1.87 g, 14.1 mmol) in CH2Cl2 (20 ml) in
the presence of triethylamine (1.1 equiv). The solution was stir-
red at 0 C for less than 1.5 h. The reaction mixture was
washed with HCl 0.1 N and water, and the organic layer was
dried over anhydrous sodium sulfate, ﬁltered and concentrated
in vacuo. The residue was puriﬁed by silica gel chromatogra-
phy to give carboxylsulfamides in good yields.
5.2.1. Tert-butyl (1-Cyclohexyl)amino sulfonylcarbamate (1a)
Yield: 90%, mp 109–110 C, Rf = 0.90 (CH2Cl2/MeOH, 9/1),
1H NMR (CDCl3, d ppm): 1.05 (s, 9H, tBu), 1.65–2.1 (m,
10H, CH2-cyc), 5.15 (d, 1H, J= 7.35, NH–CH-cyc), 7.18 (s,
1H, (NH-Boc). IR (KBr, c en cm1): 1720.1 (C‚O), 3420.5
and 3221.4 (2NH), 1367 and 1132 (SO2). SM ESI
+ 30ev
m/z: 279 [M+H]+ 100%. HRMS calcd. for C11H22N2O4S.
M = 278.
5.2.2. Tert-butyl 3,4-dihydroisoquinolin-2(1H)-yl
sulfonylcarbamate (1b)
Yield: 80%, mp 136–137 C, Rf = 0.75 (CH2Cl2/MeOH, 9/1),
1H NMR (CDCl3, d ppm): 1.5 (s, 9H, tBu), 2.90 (t,
J= 5.87 Hz, 2H, CH2–Ph), 3.30 (t, J= 6.02 Hz, 2H, CH2–
N), 4.50 (s, 2H, Ph–CH2–N), 7.1–7.6 (m, 4H, Ar–H),
7.8(s,1H, NH–Boc). IR (KBr, c en cm1): 1725.2 (C‚O),
3423.8 (NH), 1643.6 (C‚C), 1364.2 and 1133 (SO2). SM
ESI+ 30ev m/z: 313 [M+H]+ 100%. HRMS calcd. for
C14H20N2O4S. M = 312.5.2.3. Tert-butyl (1-Propyl) amino sulfonylcarbamate (1c)
Yield: 97%, mp 110–111 C, Rf = 0.80 (CH2Cl2/MeOH, 9/1),
1H NMR (CDCl3, d ppm): 1.01(t, J= 5.02 Hz, 3H, CH3),1.60 (s, 9H, tBu), 1.65 (m, 2H, CH3–CH2), 3.2 (m, 2H, CH2–
NH),5.2(t, 1H, J= 6.04 Hz, CH2–NH), 7.32 (s,1H, NH-
Boc). IR (KBr, c en cm1): 1710.5 (C‚O), 3300.4 (NH),
1370 and 1150 (SO2). SM ESI
+ 30ev m/z: 239 [M+H]+
100%. HRMS calcd. for C8H18N2O4S. M = 238.
5.3. General procedure for the N-acylation of sulfonamide
The sulfonamides (1equiv.) were reacted with acetic anhydride
(1.5 equiv.) in the presence of 0.3% of H2SO4 in acetonitrile at
80 C. After 2 h the reaction mixture was evaporated, diluted
with dichloromethane and washed with water. The combined
organic layers were dried over Na2SO4 and evaporated in va-
cuo. The crude compounds were puriﬁed by column chroma-
tography (CH2Cl2/MeOH, 9/1) to afford the corresponding
acyl sulfonamides in a good yield.
5.3.1. N-(1–cyclohexyl)amino sulfonyl ace´tamide (3a)
Yield: 87%, mp 197–198 C, Rf = 0.52 (CH2Cl2/MeOH, 9/1),
1H NMR (CDCl3, d ppm): 1.65–2.1 (m, 10H, CH2-cyc), 5.15
(d, 1H, J= 7.35, NH–CH2 cycle), 2.0 (s, 3H, CH3). IR
(KBr, c en cm1): 3372 and 3265 (2NH), 1730 (C‚O), 1360
and 1153 (SO2). SM ESI
+ 30ev m/z: 221 [M+H]+
100%.HRMS calcd. for C8H16N2O3S. M = 220.
5.3.2. N-(3,4-dihydroisoquinolin-2(1H)-yl sulfonyl) acetamide
(3b)
Yield: 65%, mp 172–173 C, Rf = 0.38 (CH2Cl2/MeOH, 9/1),
1H NMR (CDCl3, d ppm): 8.1 (s, 1H, NH), 7.2–7.0 (m, 4H,
H-Ar), 4.5 (s, 2H, ph-CH2N), 3.7 (t, 2H,J= 5.7 Hz, CH2N),
2.9 (t, 2H, J= 5.8 Hz, 2H, CH2-ph), 2.1 (s, 3H, CH3).
13C
NMR (CDCl3, d ppm): 173, 134.1, 127.5, 126.9, 126.3, 125.7,
48.1, 47.2, 25.3, 21.6. IR (KBr, c en cm1): 3260 (NH), 1711
(C‚O), 1361 and 1155 (SO2). SM ESI
+ 30ev m/z: 255
[M+H]+ 100%. HRMS calcd. for C11H14N2O3S. M = 254.
5.3.3. N-(1–propyl) amino[ sulfonyl ace´tamide (3c)
Yield: 79%, mp 167–168 C, Rf = 0.42 (CH2Cl2/MeOH, 9/1),
1H NMR (CDCl3, d ppm): 1.01 (t, J= 5.02 Hz, 3H, CH3),
1.65 (m, 2H, CH3–CH2), 3.2 (m, 2H, CH2–NH), 5.2 (t, 1H,
J= 6.23 Hz, CH2–NH), 2.1 (s, 3H, CH3). IR (KBr, c en -
cm1): 3370 and 3263 (2NH), 1721 (C‚O), 1380 and 1154
(SO2). SM ESI
+ 30ev m/z: 181 [M+H]+ 100%. HRMS calcd.
for C5H12N2O3S. M = 180.Acknowledgments
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